Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Med Chem ; 43(4): 649-63, 2000 Feb 24.
Artículo en Inglés | MEDLINE | ID: mdl-10691691

RESUMEN

A systematic investigation of the structure-activity relationships of the C-3 side chain of the screening hit 1a led to the identification of the potent thrombin inhibitors 23c, 28c, and 31c. Their activities (1240, 903, and 1271 x 10(6) L/mol, respectively) represent 2200- and 2900-fold increases in potency over the starting lead 1a. This activity enhancement was accomplished with an increase of thrombin selectivity. The in vitro anticoagulant profiles of derivatives 28c and 31c were determined, and they compare favorably with the clinical agent H-R-1-[4aS, 8aS]perhydroisoquinolyl-prolyl-arginyl aldehyde (D-Piq-Pro-Arg-H; 32). The more potent members of this series have been studied in an arterial/venous shunt (AV shunt) model of thrombosis and were found to be efficacious in reducing clot formation. However, their efficacy is currently limited by their rapid and extensive distribution following administration.


Asunto(s)
Anticoagulantes/síntesis química , Pirrolidinas/síntesis química , Inhibidores de Serina Proteinasa/síntesis química , Tiofenos/síntesis química , Trombina/antagonistas & inhibidores , Animales , Anticoagulantes/química , Anticoagulantes/farmacocinética , Anticoagulantes/farmacología , Sitios de Unión , Cristalografía por Rayos X , Evaluación Preclínica de Medicamentos , Humanos , Técnicas In Vitro , Modelos Moleculares , Pirrolidinas/química , Pirrolidinas/farmacocinética , Pirrolidinas/farmacología , Ratas , Inhibidores de Serina Proteinasa/química , Inhibidores de Serina Proteinasa/farmacocinética , Inhibidores de Serina Proteinasa/farmacología , Relación Estructura-Actividad , Tiofenos/química , Tiofenos/farmacocinética , Tiofenos/farmacología , Trombosis/sangre , Trombosis/metabolismo
3.
Fundam Appl Toxicol ; 32(2): 205-16, 1996 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-8921323

RESUMEN

High doses of LY281389 (9-N-(n-propyl)-erythromycylamine) cause cytoplasmic vacuolar changes in striated and smooth muscle characteristic of drug-induced phospholipidosis. This study characterized phospholipidosis in striated and smooth muscle of rats and dogs, compared in vivo observations with those in a cultured rat myoblast model, and attempted to confirm the lysosomal origin of the drug-induced vacuoles. Standard transmission electron microscopy and acid phosphatase cytochemistry techniques were used to evaluate ultrastructural changes in vivo and in vitro. Rats and dogs exposed to LY281389 had a time- and dose-related increase in number and size of vacuoles containing concentric lamellar figures in cardiac and skeletal muscle. Cytochemical staining of dog stomach smooth muscle for acid phosphatase, a lysosomal enzyme, stained the periphery of vacuoles that contained concentric lamellar figures. Cultured rat L6 myoblast cells were exposed to 0.25 mg LY281389/ml for 2.5, 5, 10, 20, 30, or 90 min and 2, 6, 12, 24, or 48 hr. Cell cultures exposed for 2 hr had several predominantly large, clear, membrane-bound vacuoles, and at 6 and 12 hr there were greater numbers of large vacuoles that contained increased amounts of membranous figures. Following 24- or 48-hr exposures, vacuoles occupied most of the cytoplasmic volume, and were engorged predominantly with amorphous or granular material. These findings indicate that LY281389 can induce similar phospholipidosis-like vacuolar changes in rat and dog muscle and in a cultured rat muscle cell line. Further, positive acid phosphatase staining of drug-induced vacuolar structures, in conjunction with standard transmission electron microscopy techniques, strongly suggests that vacuoles seen in vitro and in vivo are lysosomal in origin.


Asunto(s)
Antibacterianos/farmacología , Eritromicina/análogos & derivados , Músculo Liso/efectos de los fármacos , Fosfatasa Ácida/metabolismo , Animales , Línea Celular , Perros , Eritromicina/farmacología , Histocitoquímica , Microscopía Electrónica , Músculo Liso/ultraestructura , Ratas , Ratas Endogámicas F344 , Vacuolas/efectos de los fármacos
4.
Biochem Pharmacol ; 49(7): 915-9, 1995 Mar 30.
Artículo en Inglés | MEDLINE | ID: mdl-7741763

RESUMEN

Induction of peroxisome proliferator responsive genes is thought to be mediated through binding of a peroxisome proliferator-activated receptor (PPAR) to specific peroxisome proliferator response elements in the upstream region of these genes. Binding of PPAR to the acyl-CoA oxidase promoter requires heterodimerization with the retinoid X receptor (RXR), and subsequent transactivation is strongest when ligands for both PPAR and RXR are present. Therefore, we hypothesized that depletion of ligand for the retinoid receptor would limit the induction of peroxisome proliferation in rats. Hepatic retinol content was reduced by more than 90% by feeding weanling rats a vitamin A deficient (VAD) diet for approximately 3 months. Nafenopin treatment for 7 days induced peroxisomal beta-oxidation 18-fold in VAD rats compared with 16-fold in rats fed a vitamin A sufficient (VAS) diet. Nafenopin induced microsomal laurate hydroxylase and mitochondrial beta-oxidation to comparable rates of specific activity in both VAD and VAS rats. However, the activities in VAD controls were significantly lower than in VAS controls, so the magnitude of the nafenopin-induced increases was greater in the VAD rats. Relative liver weights were increased nearly 2-fold in both VAS and VAD rats treated with nafenopin. Ultrastructural examination of the livers demonstrated that nafenopin increased the number and size of peroxisomes in both VAD and VAS rats. These data demonstrate that rats with severely depleted vitamin A stores remained responsive to the peroxisome proliferator nafenopin. Whether critical retinoid pools that supply RXR ligand (9-cis-retinoic acid) are spared in the vitamin A deficient rats remains to be determined.


Asunto(s)
Hígado/efectos de los fármacos , Microcuerpos/efectos de los fármacos , Nafenopina/farmacología , Deficiencia de Vitamina A/metabolismo , Animales , Lípidos/sangre , Hígado/metabolismo , Masculino , Microcuerpos/metabolismo , Ratas , Ratas Endogámicas F344
5.
Fundam Appl Toxicol ; 16(2): 348-55, 1991 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-2055365

RESUMEN

Assessment of hepatic omega-oxidation of fatty acids by cytochrome P450IV enzymes in toxicology studies can be a means of evaluating test compound effects on peroxisomal proliferation. Routine assay of omega-oxidation, however, requires a simpler method of enzymatic analysis than currently described GC, TLC, or HPLC methods. A method depending upon selective solvent separation of radiolabeled lauric acid from radiolabeled 11- or 12-hydroxydodecanoic acid has been developed. Following enzymatic incubation and addition of 15% methanol to the acidified postincubation mixtures, partitioning with an alkane solvent such as iso-octane, cyclohexane, or n-hexane separated the lauric acid and the hydroxylated products into two immiscible phases. Approximately 97% of the substrate partitioned into the organic phase, and approximately 84% of the hydroxylated products partitioned into the aqueous phase. Subsequent quantitation of the enzymatic activity required only liquid scintillation counting of the aqueous phase. Hepatic homogenates from male rats treated with 0.01, 0.05, 0.125, and 0.25% clofibric acid in the diet for 7 days had enzyme levels 1.3, 6.1, 11.1, or 15.9 times control values, respectively, when assayed by a conventional TLC method, and 1.3, 5.3, 12.3, or 15.3 times control values when assayed by the solvent partition method. The data indicate that the partition method demonstrates comparable sensitivity and better precision and linearity than a more conventional TLC method when induction of hepatic microsomal enzymes in rats is studied.


Asunto(s)
Ácidos Láuricos/metabolismo , Hígado/metabolismo , Animales , Cromatografía en Capa Delgada , Ácido Clofíbrico/farmacología , Hígado/efectos de los fármacos , Hígado/enzimología , Masculino , Oxidación-Reducción , Ratas , Ratas Endogámicas F344 , Solventes
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...